The Babraham Institute Revenue and Competitors

Location

N/A

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • The Babraham Institute's estimated annual revenue is currently $58.6M per year.(i)
  • The Babraham Institute's estimated revenue per employee is $127,500

Employee Data

  • The Babraham Institute has 460 Employees.(i)

The Babraham Institute's People

NameTitleEmail/Phone
1
Graduate Studies OfficerReveal Email/Phone
2
Head Governance and ProjectsReveal Email/Phone
3
Human Resources OfficerReveal Email/Phone
4
Head Information TechnologyReveal Email/Phone
5
Head Human ResourcesReveal Email/Phone
6
Head Research Operations & Deputy Director, OperationsReveal Email/Phone
7
Head CommunicationsReveal Email/Phone
8
Head Immunology Programme/ Associate Institute DirectorReveal Email/Phone
9
Knowledge Exchange and Commercialisation OfficerReveal Email/Phone
10
Grants OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.1M69-13%$16.5MN/A
#2
$264.2M1850-1%N/AN/A
#3
$51.9M401-10%$12.6MN/A
#4
$22.5M205-39%$63.8MN/A
#5
$1.1M21-19%$781.7KN/A
#6
$21.3M19033%N/AN/A
#7
$11.9M11710%N/AN/A
#8
$3.8M46-10%N/AN/A
#9
$8.8M86-16%N/AN/A
#10
$2.5M31-40%N/AN/A
Add Company

What Is The Babraham Institute?

The Babraham Institute receives funding from the Biotechnology and Biological Sciences Research Council (BBSRC) and carries out world-leading research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. Our research is focussed on four main science programmes; Epigenetics - a branch of genetics research which studies modifications to DNA that affect gene activity, it helps to explain how our environment and lifestyle can affect our behavior or likelihood of getting diseases. Immunology - the study of the immune system, which recognises and fights diseases in our bodies. Research in this area can lead to improvements in vaccines, combat autoimmune disease, develop tumour immunotherapy or improve the efficiency of organ transplantation. Signalling - researching communication within and between the cells in our body, which underpins how cells and organs develop and respond to changes in their environment, vital for maintaining health. Research in this area is identifying new targets for treatment of cancer. Nuclear Dynamics - studying how DNA is packaged inside the cells in order for the genome to function correctly. This is shedding light on why we may have susceptibility to developing cancers as well as providing insight into the coordination of gene expression and physiological functions in relation to health and ageing. Epigenetics, Nuclear Dynamics, Signalling, Immunology

keywords:N/A

N/A

Total Funding

460

Number of Employees

$58.6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

The Babraham Institute News

2022-04-06 - Old skins cells reprogrammed to regain youthful function ...

Research from the Babraham Institute has developed a method to 'time jump' human skin cells by 30 years, turning back the ageing clock for...

2022-04-06 - Rejuvenation of woman's skin could tackle diseases of ageing

The head of the team, Prof Wolf Reik, of the Babraham Institute in Cambridge, told BBC News that he hoped that the technique could...

2022-04-06 - Scientists rejuvenated the skin of a woman aged 53, de-aged 30 years

Babraham Institute in Cambridge announced on Thursday researchers had successfully rejuvenated skin cells. · Scientists reprogrammed adult skin...

2021-11-05 - Limiting inflammation may improve ‘flu vaccination response in older people

Limiting inflammation may improve ‘flu vaccination response in older people 05-11-2021 By analysing immune responses across people of different ages after seasonal influenza vaccination, immunologists at the Babraham Institute have shown that a particular type of white blood cell, circulating ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$93.1M4636%N/A
#2
$84.1M464-17%N/A
#3
$105.5M46935%N/A
#4
$155.3M4710%$402.8M
#5
N/A4737%N/A